P1–109: Inhibition of BACE1 reduces beta‐amyloid 1–40 but not N‐terminal‐truncated beta‐amyloid
Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), David Riddell(Eli Lilly (United States)), Stephen Noell(Pfizer (United States)), Claude Ambroise(Pfizer (United States)), Leslie R. Pustilnik(Pfizer (United States)), Christine Oborski(ProterixBio (United States)), Michael A. Brodney(Vertex Pharmaceuticals (United States)), ONeill Brian(Pfizer (United States)), Charles E. Nolan(Pfizer (United States))
Cited by 0
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302